The Only Press Coverage That Will Count
The only press coverage that will make a useful, continuing share price difference for AVXL will be continuing and replicated press reports in the popular media of clinical trial participants experiencing significant symptomatic improvements.
Because of blinded trials, some believe such reports could only appear after the trials are completed and results are formally announced. If so, for the Rett trial, nothing in the press for Anavex shareholders until next year.
But, take for example the Rett participants; all little girls (the Rett gene is sex-linked; kills little boys with it on their single X chromosome, but little girls, with two X chromosomes, can have one X chromosome with a normal gene, allowing them to have severe symptoms but survive). Among other debilities of the disease are sleep problems. What happens if a good number of the first little girls dosed with Anavex 2-73 begin to sleep well? Would a number of enthusiastic mothers telling that to news writers or reporters be silenced? Would there be a news article there? Would it appear in the media somewhere?
Now if it were but one or two Rett girls and their mothers, no story. But five, then six, then ten? (I'd love to write that story. But someone else will, when it evolves.)
AI
Market Data 
Markets 
